Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.
Saved in:
| Title: | Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. |
|---|---|
| Authors: | Omange WR; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Varco-Merth BD; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Fadeyi O; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Marenco A; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Takata H; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Duell DM; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Goodwin WD; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Armitage P; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Kose E; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Immonen TT; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Kosmider E; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Bosche WJ; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Fast R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Homick C; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Oswald K; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Shoemaker R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Bochart R; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., MacAllister R; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Labriola CS; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Smedley JV; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Axthelm MK; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Edlefsen PT; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Gergen J; CureVac SE, Tübingen, Germany., Petsch B; CureVac SE, Tübingen, Germany., Rauch S; CureVac SE, Tübingen, Germany., Picker LJ; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Okoye AA; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2026 Jan 29; Vol. 136 (6). Date of Electronic Publication: 2026 Jan 29 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41609736 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Omange+WR%22">Omange WR</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Varco-Merth+BD%22">Varco-Merth BD</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Fadeyi+O%22">Fadeyi O</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Marenco+A%22">Marenco A</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Takata+H%22">Takata H</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Duell+DM%22">Duell DM</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Goodwin+WD%22">Goodwin WD</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Armitage+P%22">Armitage P</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Fennessey+CM%22">Fennessey CM</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kose+E%22">Kose E</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Immonen+TT%22">Immonen TT</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kosmider+E%22">Kosmider E</searchLink>; Fred Hutchinson Cancer Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Bosche+WJ%22">Bosche WJ</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Fast+R%22">Fast R</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Homick+C%22">Homick C</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Oswald+K%22">Oswald K</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Shoemaker+R%22">Shoemaker R</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Bochart+R%22">Bochart R</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22MacAllister+R%22">MacAllister R</searchLink>; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Labriola+CS%22">Labriola CS</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Smedley+JV%22">Smedley JV</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Axthelm+MK%22">Axthelm MK</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Edlefsen+PT%22">Edlefsen PT</searchLink>; Fred Hutchinson Cancer Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Keele+BF%22">Keele BF</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Lifson+JD%22">Lifson JD</searchLink>; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Gergen+J%22">Gergen J</searchLink>; CureVac SE, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Petsch+B%22">Petsch B</searchLink>; CureVac SE, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Rauch+S%22">Rauch S</searchLink>; CureVac SE, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Picker+LJ%22">Picker LJ</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Okoye+AA%22">Okoye AA</searchLink>; Vaccine and Gene Therapy Institute and.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227802877%22">The Journal of clinical investigation</searchLink> [J Clin Invest] 2026 Jan 29; Vol. 136 (6). <i>Date of Electronic Publication: </i>2026 Jan 29 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7802877 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1558-8238 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200219738%22">00219738 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Invest <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41609736 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1172/JCI198294 Languages: – Code: eng Text: English Titles: – TitleFull: Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Omange WR – PersonEntity: Name: NameFull: Varco-Merth BD – PersonEntity: Name: NameFull: Fadeyi O – PersonEntity: Name: NameFull: Marenco A – PersonEntity: Name: NameFull: Takata H – PersonEntity: Name: NameFull: Duell DM – PersonEntity: Name: NameFull: Goodwin WD – PersonEntity: Name: NameFull: Armitage P – PersonEntity: Name: NameFull: Fennessey CM – PersonEntity: Name: NameFull: Kose E – PersonEntity: Name: NameFull: Immonen TT – PersonEntity: Name: NameFull: Kosmider E – PersonEntity: Name: NameFull: Bosche WJ – PersonEntity: Name: NameFull: Fast R – PersonEntity: Name: NameFull: Homick C – PersonEntity: Name: NameFull: Oswald K – PersonEntity: Name: NameFull: Shoemaker R – PersonEntity: Name: NameFull: Bochart R – PersonEntity: Name: NameFull: MacAllister R – PersonEntity: Name: NameFull: Labriola CS – PersonEntity: Name: NameFull: Smedley JV – PersonEntity: Name: NameFull: Axthelm MK – PersonEntity: Name: NameFull: Edlefsen PT – PersonEntity: Name: NameFull: Keele BF – PersonEntity: Name: NameFull: Lifson JD – PersonEntity: Name: NameFull: Gergen J – PersonEntity: Name: NameFull: Petsch B – PersonEntity: Name: NameFull: Rauch S – PersonEntity: Name: NameFull: Picker LJ – PersonEntity: Name: NameFull: Okoye AA IsPartOfRelationships: – BibEntity: Dates: – D: 29 M: 01 Text: 2026 Jan 29 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1558-8238 Numbering: – Type: volume Value: 136 – Type: issue Value: 6 Titles: – TitleFull: The Journal of clinical investigation Type: main |
| ResultId | 1 |